5-HT.sub.4 receptor antagonist
    42.
    发明授权
    5-HT.sub.4 receptor antagonist 失效
    5-HT4受体拮抗剂

    公开(公告)号:US5741801A

    公开(公告)日:1998-04-21

    申请号:US553390

    申请日:1995-11-22

    CPC分类号: C07D401/06

    摘要: Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: X--CO--CH.sub.2 --Z (I) wherein X is a monocyclic or polycyclic aromatic group, Z is of sub-formula (h), (j) or (k): ##STR1## wherein n.sup.1 is 1, 2, 3 or 4; n.sup.2 is 0, 1, 2, 3 or 4; n.sup.3 is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2; R.sub.5 is hydrogen, C.sub.1-12 alkyl, aralkyl or R.sub.5 is (CH.sub.2).sub.z --R.sub.10 wherein z is 2 or 3 and R.sub.10 is selected from cyano, hydroxyl, C.sub.1-6 alkoxy, phenoxy, C(O)C.sub.1-6 alkyl, COC.sub.6 H.sub.5, --CONR.sub.11 R.sub.12, NR.sub.11 COR.sub.12, SO.sub.2 NR.sub.11 R.sub.12 or NR.sub.11 SO.sub.2 R.sub.12 wherein R.sub.11 and R.sub.12 are hydrogen or C.sub.1-6 alkyl; or R.sub.5 is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C.sub.2-7 alkoxycarbonyl, or secondary or tertiary hydroxy substituted C.sub.1-6 alkyl; and R.sub.6, R.sub.7 and R.sub.8 are independently hydrogen or C.sub.1-6 alkyl; and R.sub.9 is hydrogen or C.sub.1-10 alkyl; and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders are provided.

    摘要翻译: PCT No.PCT / EP94 / 01583 Sec。 371日期:1995年11月22日 102(e)日期1995年11月22日PCT 1994年5月16日PCT PCT。 第WO94 / 27987号公报 日期:1994年12月8日,式(I)化合物及其药学上可接受的盐,以及式(I)化合物或其药学上可接受的盐的用途:X-CO-CH 2 -Z(I)其中X是单环 或多环芳族基团,Z为亚式(h),(j)或(k):其中n1为1,2,3或(k)其中n1为1,2,3或 4; n2为0,1,2,3或4; n3为2,3,4或5; q为0,1,2或3; p为0,1或2; m为0,1或2; R5是氢,C1-12烷基,芳烷基或R5是(CH2)z-R10,其中z是2或3,R10选自氰基,羟基,C1-6烷氧基,苯氧基,C(O)C1-6烷基, COC6H5,-CONR11R12,NR11COR12,SO2NR11R12或NR11SO2R12,其中R11和R12是氢或C1-6烷基; 或R5是由芳基末端取代的链长1-6个碳原子的直链或支链亚烷基,3至8元环烷基,3至8元杂环基,5或6元单环杂芳基或通过碳键连接的9或10元稠合双环杂芳基 ,C 2-7烷氧基羰基或仲或叔羟基取代的C 1-6烷基; 并且R 6,R 7和R 8独立地为氢或C 1-6烷基; 并且R 9为氢或C 1-10烷基; 并且提供它们作为药物用于治疗胃肠道疾病,心血管疾病和CNS障碍的用途。

    Phenylpyrrole derivatives and their use as antipsychotic agents
    44.
    发明授权
    Phenylpyrrole derivatives and their use as antipsychotic agents 失效
    苯基吡咯衍生物及其作为抗精神病药的用途

    公开(公告)号:US5688790A

    公开(公告)日:1997-11-18

    申请号:US532548

    申请日:1995-09-28

    CPC分类号: C07D471/04 C07D455/02

    摘要: This invention relates to compounds of formula (I): ##STR1## wherein R.sup.1 represents C.sub.1-4 alkyl; and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 each independently represent hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkoxyC.sub.1-4 alkyl, C.sub.1-4 alkylsulphonyl, trifluoromethylsulphonyl; optionally substituted arylsulphonyl, optionally substituted heteroarylsulphonyl, optionally substituted aralkylsulphonyl, optionally substituted heteroaralkylsulphonyl, nitro, cyano, amino, mono- or di-alkylamino, trifluoromethyl, trifluoromethoxy, hydroxyl, hydroxyC.sub.1-4 alkyl, C.sub.1-4 alkylthio, C.sub.1-4 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, or mono- or diC.sub.1-4 alkylaminosulphonyl; or R.sup.1 and R.sup.2 together form a linking chain --(CH.sub.2).sub.m Op; (wherein m is 2 to 4 and p is zero or 1) which chain may be optionally substituted by one or two C.sub.1-4 alkyl groups; and Y represents a group of formula (.alpha.): ##STR2## wherein each of n and m independently represent an integer from 1 to 3; and salts thereof, having activity at dopamine receptors and potential utility in the treatment of psychoses such as schizophrenia.

    摘要翻译: PCT No.PCT / EP94 / 00992 Sec。 371 1995年9月28日第 102(e)日期1995年9月28日PCT 1994年3月29日PCT公布。 公开号WO94 / 24129 日本公开专利文献1:日本专利公开公报发明内容本发明涉及式(I)的化合物:其中R 1表示C 1-4烷基的式(I) 并且R 2,R 3,R 4和R 5各自独立地表示氢,卤素,C 1-4烷基,C 1-4烷氧基,C 1-4烷氧基C 1-4烷基,C 1-4烷基磺酰基,三氟甲基磺酰基; 任选取代的芳基磺酰基,任选取代的芳基磺酰基,任选取代的芳烷基磺酰基,任选取代的杂芳烷基磺酰基,硝基,氰基,氨基,一或二 - 烷基氨基,三氟甲基,三氟甲氧基,羟基,羟基C 1-4烷基,C 1-4烷硫基,C 1-4烷酰基,C 1-4烷氧基羰基 ,氨基磺酰基,或单或二C 1-4烷基氨基磺酰基; 或R 1和R 2一起形成连接链 - (CH 2)mOp; (其中m为2〜4,p为0或1),该链可以任选被一个或两个C 1-4烷基取代; 并且Y表示式(α)的基团:其中n和m各自独立地表示1至3的整数; 及其盐,其在多巴胺受体上具有活性,在治疗精神病如精神分裂症中具有潜在的用途。

    Supersaturated topical compositions
    47.
    发明授权
    Supersaturated topical compositions 失效
    过饱和局部组合物

    公开(公告)号:US5631248A

    公开(公告)日:1997-05-20

    申请号:US318614

    申请日:1994-10-07

    IPC分类号: A61K9/06 A61K9/08 A61K9/70

    CPC分类号: A61K9/08 Y10S514/944

    摘要: Two-component pharmaceutical compositions for topical application to the human or animal body comprising two miscible liquid phases having different lipophilicities and a drug dissolved in at least one liquid phase, each phase comprising at least one topically acceptable non-aqueous and non-volatile solvent.

    摘要翻译: PCT No.PCT / GB93 / 00692 Sec。 371日期:1994年10月7日 102(e)日期1994年10月7日PCT提交1993年4月2日PCT公布。 WO93 / 20799 PCT出版物 日期:1993年10月28日用于局部施用于人或动物体的两组分药物组合物,其包含两种具有不同亲油性的可混溶的液相和溶解在至少一个液相中的药物,每相包含至少一种局部可接受的非水性和 非挥发性溶剂。